Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma. Issue 4 (April 2015)

• Record Type: Journal Article
• Authors: Lee, Gyeong-Won; Go, Se-Il; Kim, Seok-Hyun; Hong, Junshik; Kim, Yu Ri; Oh, Sukjoong; Kim, Sung-Yong; Do, Young Rok; Lee, Hyewon; Lee, Soon Il; Bae, Sung Hwa; Oh, Sung Yong; Song, Moo Kon; Lee, Won-Sik; Lee, Bohee; Kim, Jin Seok; Kim, Min Kyoung; Kang, Hye Jin; Ahn, Jae-Sook; Yhim, Ho-Young; Kim, Hyo Jung; Kim, Seok Jin; Kim, Won Seog; Suh, Cheolwon; for the Consortium for Improving Survival of Lymphoma (CISL) study group
• Is Part Of: Leukemia & lymphoma. Volume 56:Issue 4(2015:Apr.)
• Page Start: 1020
• Page End: 1026
• Publication Date: 2015-04
• Subjects: Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2014.946027
• Languages: English
• ISSNs: 1042-8194

Abstract

<abstract> <title>Abstract</title> <p>We evaluated the clinical outcomes and relapse patterns of 80 patients with primary sinonasal tract diffuse large B-cell lymphoma (SN-DLBCL) treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy at 22 institutions. A total of 59 (73.8%) patients received R-CHOP chemotherapy alone, whereas 21 (26.3%) were treated with R-CHOP followed by involved field radiotherapy (IFRT). In 73 patients with Ann Arbor stage I–II disease, no significant difference was found in the response rate or overall survival (OS) between R-CHOP alone (<italic>n</italic> = 52) and R-CHOP followed by IFRT (<italic>n</italic> = 21). Among 11 relapsed patients in this study, the most common pattern of relapse was local (<italic>n</italic> = 8, 11.8%), whereas central nervous system (CNS) relapse was observed in only one (1.9%) patient. These results suggest that patients with primary SN-DLBCL treated with R-CHOP have a relatively low CNS relapse rate and better OS compared to previous studies before the introduction of R.</p> </abstract>